Dr. Susan Leeman is a Professor in the Department of Pharmacology & Experimental Therapeutics, and the Director of the Neuropeptide Laboratory in the Pharmacology Department at the Boston University School of Medicine. Dr. Leeman has been a Member of the National Academy of Sciences since 1991.
Dr. Leeman’s research focuses on the two peptides, substance P (SP) and neurotensin, that were isolated and chemically defined in this laboratory. Previous projects that are currently underway relating to the biochemistry and pharmacology of SP include studies to determine the binding domains of SP with its receptor using photoactivatable derivatives of SP containing the photoreactive amino acid benzoylphenlalanine; studies to determine the binding domains of an antagonist of SP, CP 96,345 using a photoactivatable derivative of this compound; the characterization of calcium signals generated by administration of SP to CHO cells transfected with mRNA encoding the full-length SP receptor; the roles of SP in several models of inflammation in the gastrointestinal tract using non-peptide SP antagonists; a truncated form of the SP receptor and several mutant receptors. A new direction of research involves studies directed towards the chemical characterization and function of the carbohydrate moieties on the SP receptor.
- Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences
- Radcliffe College, PhD
- Radcliffe College, MA
- Goucher College, BA
- Published on 10/7/2019
Tsilioni I, Patel AB, Pantazopoulos H, Berretta S, Conti P, Leeman SE, Theoharides TC. IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin. Proc Natl Acad Sci U S A. 2019 Oct 22; 116(43):21659-21665. PMID: 31591201.
- Published on 11/1/2018
Theoharides TC, Leeman SE. Effect of IL-33 on de novo synthesized mediators from human mast cells. J Allergy Clin Immunol. 2019 01; 143(1):451. PMID: 30390921.
- Published on 9/19/2018
Taracanova A, Tsilioni I, Conti P, Norwitz ER, Leeman SE, Theoharides TC. Substance P and IL-33 administered together stimulate a marked secretion of IL-1ß from human mast cells, inhibited by methoxyluteolin. Proc Natl Acad Sci U S A. 2018 10 02; 115(40):E9381-E9390. PMID: 30232261.
- Published on 6/27/2018
Douglas SD, Leeman SE. Is substance P a nasal epithelial neuropeptide? J Allergy Clin Immunol. 2018 11; 142(5):1677. PMID: 29958676.
- Published on 11/6/2017
Theoharides TC, Taracanova A, Tsilioni I, Conti P, Leeman SE. Reply to Fattori et al.: Action of SP and IL-33 on mast cells. Proc Natl Acad Sci U S A. 2017 11 21; 114(47):E10036. PMID: 29109296.
- Published on 5/1/2017
Taracanova A, Alevizos M, Karagkouni A, Weng Z, Norwitz E, Conti P, Leeman SE, Theoharides TC. SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proc Natl Acad Sci U S A. 2017 05 16; 114(20):E4002-E4009. PMID: 28461492.
- Published on 9/23/2016
Patel AB, Tsilioni I, Leeman SE, Theoharides TC. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proc Natl Acad Sci U S A. 2016 Nov 08; 113(45):E7049-E7058. PMID: 27663735.
- Published on 12/9/2013
Yuan H, Zelka S, Burkatovskaya M, Gupte R, Leeman SE, Amar S. Pivotal role of NOD2 in inflammatory processes affecting atherosclerosis and periodontal bone loss. Proc Natl Acad Sci U S A. 2013 Dec 24; 110(52):E5059-68. PMID: 24324141.
- Published on 11/11/2013
Burke RM, Norman TA, Haydar TF, Slack BE, Leeman SE, Blusztajn JK, Mellott TJ. BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2013 Nov 26; 110(48):19567-72. PMID: 24218590.
- Published on 8/5/2013
Amar S, Leeman S. Periodontal innate immune mechanisms relevant to obesity. Mol Oral Microbiol. 2013 Oct; 28(5):331-41. PMID: 23911141.
View 211 more publications: View full profile at BUMC